Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.64) per share. This is a 8.57 percent increase over losses of $(0.70) per share from the same period last year.
Morgan Stanley Maintains Overweight on T-Mobile US, Lowers Price Target to $175
Morgan Stanley analyst Simon Flannery maintains T-Mobile US (NASDAQ:TMUS) with a Overweight and lowers the price target from $180 to $175.